LOGIN
Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain
October 2018
Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trial
Clin Ther. 2015 Oct 1;37(10):2267-74. doi: 10.1016/j.clinthera.2015.07.023Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
13 patients diagnosed with non-cardiac chest pain were randomly assigned to orally consume twice a day for 4 weeks either 5mg dronabinol capsules or placebo capsules. Metabolic parameters such as body mass index, various cholesterol levels, triglyceride level, plasma glucose level, insulin and leptin level, and high-sensitivity C-reactive protein level were assessed at the beginning and end of the...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.